Facilitating earlier diagnosis of cardiovascular disease through point-of-care biosensors: A review

Mackenzie M. Honikel, Chi En Lin, David Probst, Jeffrey LaBelle

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) accounts for 30% of all global deaths and is predicted to dominate in the coming years, despite vast improvements in medical technology. Current clinical methods of assessing an individual’s cardiovascular health include blood tests to monitor relevant biomarker levels as well as varying imaging modalities such as electrocardiograms, computed tomography, and angiograms to assess vasculature. As informative as these tools are, they each require lengthy scheduling, preparation, and highly trained personnel to interpret the results before any information is accessible to patients, often leading to delayed treatment, which can be fatal. A point-of-care (POC) sensor platform is thus paramount in rapid and early diagnosis of CVD. Among the many POC detection platforms, including established optical and mechanical methods, electrochemical-based detection mechanisms have become increasingly desirable because of their superior sensitivity, low cost, and label-free detection. Specifically, electrochemical impedance spectroscopy (EIS) has demonstrated remarkable abilities in low-level (femtomolar) detection of several clinically useful biomarkers and has been reported in CVD diagnostic applications. In this review, we provide an in-depth overview of prevalent CVD diseases and clinically relevant proteomic biomarkers for assessing them. Subsequently, we discuss the ongoing development of POC sensors for CVD, highlighting the current clinical gold standard, potential alternative modalities, and electrochemical methodologies previously successful in quantifying specific biomarkers approved by the Food and Drug Administration (FDA). A discussion of EIS highlighting the attributes and capabilities of novel analysis algorithms is included to showcase the possibility of simultaneous dual-marker detection.

Original languageEnglish (US)
Pages (from-to)53-82
Number of pages30
JournalCritical Reviews in Biomedical Engineering
Volume46
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Biosensors
Biomarkers
Electrochemical impedance spectroscopy
Sensors
Electrocardiography
Tomography
Labels
Blood
Scheduling
Health
Personnel
Imaging techniques
Costs

Keywords

  • Biomarker
  • Cardiovascular disease
  • Early detection
  • Electrochemical impedance spectroscopy
  • Imaginary impedance
  • Label-free detection
  • Optimal frequency algorithm

ASJC Scopus subject areas

  • Biomedical Engineering

Cite this

Facilitating earlier diagnosis of cardiovascular disease through point-of-care biosensors : A review. / Honikel, Mackenzie M.; Lin, Chi En; Probst, David; LaBelle, Jeffrey.

In: Critical Reviews in Biomedical Engineering, Vol. 46, No. 1, 01.01.2018, p. 53-82.

Research output: Contribution to journalReview article

Honikel, Mackenzie M. ; Lin, Chi En ; Probst, David ; LaBelle, Jeffrey. / Facilitating earlier diagnosis of cardiovascular disease through point-of-care biosensors : A review. In: Critical Reviews in Biomedical Engineering. 2018 ; Vol. 46, No. 1. pp. 53-82.
@article{f435e73af33641a1b049eb2d00b725e1,
title = "Facilitating earlier diagnosis of cardiovascular disease through point-of-care biosensors: A review",
abstract = "Cardiovascular disease (CVD) accounts for 30{\%} of all global deaths and is predicted to dominate in the coming years, despite vast improvements in medical technology. Current clinical methods of assessing an individual’s cardiovascular health include blood tests to monitor relevant biomarker levels as well as varying imaging modalities such as electrocardiograms, computed tomography, and angiograms to assess vasculature. As informative as these tools are, they each require lengthy scheduling, preparation, and highly trained personnel to interpret the results before any information is accessible to patients, often leading to delayed treatment, which can be fatal. A point-of-care (POC) sensor platform is thus paramount in rapid and early diagnosis of CVD. Among the many POC detection platforms, including established optical and mechanical methods, electrochemical-based detection mechanisms have become increasingly desirable because of their superior sensitivity, low cost, and label-free detection. Specifically, electrochemical impedance spectroscopy (EIS) has demonstrated remarkable abilities in low-level (femtomolar) detection of several clinically useful biomarkers and has been reported in CVD diagnostic applications. In this review, we provide an in-depth overview of prevalent CVD diseases and clinically relevant proteomic biomarkers for assessing them. Subsequently, we discuss the ongoing development of POC sensors for CVD, highlighting the current clinical gold standard, potential alternative modalities, and electrochemical methodologies previously successful in quantifying specific biomarkers approved by the Food and Drug Administration (FDA). A discussion of EIS highlighting the attributes and capabilities of novel analysis algorithms is included to showcase the possibility of simultaneous dual-marker detection.",
keywords = "Biomarker, Cardiovascular disease, Early detection, Electrochemical impedance spectroscopy, Imaginary impedance, Label-free detection, Optimal frequency algorithm",
author = "Honikel, {Mackenzie M.} and Lin, {Chi En} and David Probst and Jeffrey LaBelle",
year = "2018",
month = "1",
day = "1",
doi = "10.1615/CritRevBiomedEng.2018025818",
language = "English (US)",
volume = "46",
pages = "53--82",
journal = "Critical Reviews in Biomedical Engineering",
issn = "0278-940X",
publisher = "Begell House Inc.",
number = "1",

}

TY - JOUR

T1 - Facilitating earlier diagnosis of cardiovascular disease through point-of-care biosensors

T2 - A review

AU - Honikel, Mackenzie M.

AU - Lin, Chi En

AU - Probst, David

AU - LaBelle, Jeffrey

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cardiovascular disease (CVD) accounts for 30% of all global deaths and is predicted to dominate in the coming years, despite vast improvements in medical technology. Current clinical methods of assessing an individual’s cardiovascular health include blood tests to monitor relevant biomarker levels as well as varying imaging modalities such as electrocardiograms, computed tomography, and angiograms to assess vasculature. As informative as these tools are, they each require lengthy scheduling, preparation, and highly trained personnel to interpret the results before any information is accessible to patients, often leading to delayed treatment, which can be fatal. A point-of-care (POC) sensor platform is thus paramount in rapid and early diagnosis of CVD. Among the many POC detection platforms, including established optical and mechanical methods, electrochemical-based detection mechanisms have become increasingly desirable because of their superior sensitivity, low cost, and label-free detection. Specifically, electrochemical impedance spectroscopy (EIS) has demonstrated remarkable abilities in low-level (femtomolar) detection of several clinically useful biomarkers and has been reported in CVD diagnostic applications. In this review, we provide an in-depth overview of prevalent CVD diseases and clinically relevant proteomic biomarkers for assessing them. Subsequently, we discuss the ongoing development of POC sensors for CVD, highlighting the current clinical gold standard, potential alternative modalities, and electrochemical methodologies previously successful in quantifying specific biomarkers approved by the Food and Drug Administration (FDA). A discussion of EIS highlighting the attributes and capabilities of novel analysis algorithms is included to showcase the possibility of simultaneous dual-marker detection.

AB - Cardiovascular disease (CVD) accounts for 30% of all global deaths and is predicted to dominate in the coming years, despite vast improvements in medical technology. Current clinical methods of assessing an individual’s cardiovascular health include blood tests to monitor relevant biomarker levels as well as varying imaging modalities such as electrocardiograms, computed tomography, and angiograms to assess vasculature. As informative as these tools are, they each require lengthy scheduling, preparation, and highly trained personnel to interpret the results before any information is accessible to patients, often leading to delayed treatment, which can be fatal. A point-of-care (POC) sensor platform is thus paramount in rapid and early diagnosis of CVD. Among the many POC detection platforms, including established optical and mechanical methods, electrochemical-based detection mechanisms have become increasingly desirable because of their superior sensitivity, low cost, and label-free detection. Specifically, electrochemical impedance spectroscopy (EIS) has demonstrated remarkable abilities in low-level (femtomolar) detection of several clinically useful biomarkers and has been reported in CVD diagnostic applications. In this review, we provide an in-depth overview of prevalent CVD diseases and clinically relevant proteomic biomarkers for assessing them. Subsequently, we discuss the ongoing development of POC sensors for CVD, highlighting the current clinical gold standard, potential alternative modalities, and electrochemical methodologies previously successful in quantifying specific biomarkers approved by the Food and Drug Administration (FDA). A discussion of EIS highlighting the attributes and capabilities of novel analysis algorithms is included to showcase the possibility of simultaneous dual-marker detection.

KW - Biomarker

KW - Cardiovascular disease

KW - Early detection

KW - Electrochemical impedance spectroscopy

KW - Imaginary impedance

KW - Label-free detection

KW - Optimal frequency algorithm

UR - http://www.scopus.com/inward/record.url?scp=85046116177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046116177&partnerID=8YFLogxK

U2 - 10.1615/CritRevBiomedEng.2018025818

DO - 10.1615/CritRevBiomedEng.2018025818

M3 - Review article

C2 - 29717677

AN - SCOPUS:85046116177

VL - 46

SP - 53

EP - 82

JO - Critical Reviews in Biomedical Engineering

JF - Critical Reviews in Biomedical Engineering

SN - 0278-940X

IS - 1

ER -